- July 28, 2010
- In drug Recalls
On July 16, 2010, the Food and Drug Administration (FDA) decided to keep the diabetes drug Avandia (rosiglitazone) on the market despite a cardiovascular threat to some patients. Conflicting studies have shown that the drug rosiglitazone promotes increased cardiovascular risk to patients with diabetes.
The FDA, as well as the Endocrine Society, the American Association of Clinical Endocrinologists and the American Diabetes Association, have issued warnings that stopping the drug abruptly may cause a patient more serious short-term health problems and complications.
It is the recommendation of the Southern California drug recall attorneys at the Law Offices of Samer Habbas to speak to your doctor before discontinuing any medication. Oftentimes, people hear reports on the news about defective drugs and suddenly stop taking their medication. The withdrawal effects of abruptly stopping any diabetes medication can result in a rise in blood glucose that can cause complications in the future.
There are alternative medications other than Avandia for diabetes that you can consider if you are at a high risk for cardiovascular episodes. Call your healthcare care provider as soon as possible to determine whether one of these other medications would be right for you.
If you have experienced health problems due to Avandia, you should report them to your doctor right away. You should write down what happened each time and keep the medication bottle. Keeping accurate records of any Avandia drug complications would be crucial if stores pull the product from their shelves.
At The Law Offices of Samer Habbas, we have a team of drug recall attorneys who are here to answer any questions you have. Feel free to call us with questions about the Avandia drug recall at 888.848.5084 or visit our website for up-to-date news on how our civil litigation department is helping clients who have taken defective medication.
Tags : drug Recalls
July 29, 2020
July 2, 2020
June 19, 2020
June 15, 2020
June 12, 2020